Abstract Number: 1842 • 2016 ACR/ARHP Annual Meeting
Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is a kind of chronic and autoimmune disease with variable multi-system involvement of unknown causes, which is characterized by periods…Abstract Number: 2791 • 2016 ACR/ARHP Annual Meeting
Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease displaying a heavy female predominance during reproductive years. We have previously shown that toll-like receptor…Abstract Number: 2812 • 2016 ACR/ARHP Annual Meeting
Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans
Background/Purpose: Clinical trials of patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) can be confounded by difficulties in engaging patients. Identifying factors of…Abstract Number: 747 • 2015 ACR/ARHP Annual Meeting
Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher incidence of thrombotic thrombocytopenic purpura (TTP). Differentiating TTP from SLE activity may represent a challenge…Abstract Number: 780 • 2015 ACR/ARHP Annual Meeting
Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by fluctuating disease activity over periods of years. The estimated 5-year survival rate of…Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…Abstract Number: 2935 • 2015 ACR/ARHP Annual Meeting
Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Background/Purpose: To compare clinical features, disease activity and outcome in late onset versus early onset SLE over 5 years of follow up. Methods: Patients with…Abstract Number: 2953 • 2015 ACR/ARHP Annual Meeting
The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Background/Purpose: There is sparse data examining the characteristics of SLE patients who frequent the emergency room (ER). Data suggest that lupus patients with certain sociodemographic…Abstract Number: 3218 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: To assess the efficacy and safety of belimumab (BEL) administered subcutaneously plus standard SLE care (SoC) in patients with active SLE.Methods: BLISS-SC (BEL112341; NCT01484496)…Abstract Number: 737 • 2015 ACR/ARHP Annual Meeting
A Paper Patient-Based Flare Study in SLE
ACR Abstract – A Paper Patient-Based Flare Study in Systemic Lupus Erythematosus (SLE) Isenberg D, Sturgess J, Allan E, Aranow C, Aringer M, Askanase A,…Abstract Number: 2689 • 2014 ACR/ARHP Annual Meeting
The CUL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus
Background/Purpose: CC-220 is an immunomodulatory compound that binds to cereblon (CRBN), part of the CUL4CRBN E3 ubiquitin ligase complex, which has been shown to ubiquitinate…Abstract Number: 2667 • 2014 ACR/ARHP Annual Meeting
First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy
Background/Purpose: Preeclampsia complicates up to 35% of lupus pregnancies compared to 8% of general population pregnancies. SLE has up to a 3-fold increased rate of…Abstract Number: 2635 • 2014 ACR/ARHP Annual Meeting
Noncalcified Plaque Progression in Systemic Lupus Erythematosus
Background/Purpose: Coronary atherosclerosis is a major cause of morbidity and mortality in SLE. New technology, computed tomoangiography (CTA) can measure non-calcified coronary plaque (NCP),…Abstract Number: 2648 • 2014 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Background/Purpose: Depression affects as many as 30% of SLE patients. Most studies of risk factors for depression among SLE patients have been cross-sectional, and thus…Abstract Number: 2647 • 2014 ACR/ARHP Annual Meeting
Predictors of Incident Seizure in Systemic Lupus Erythematosus
Background/Purpose: We identified the rate and risk factors for first occurrences of seizure based on a large closely followed longitudinal cohort of patients with systemic…
- « Previous Page
- 1
- …
- 143
- 144
- 145
- 146
- 147
- …
- 150
- Next Page »